Minireviews
Copyright ©2013 Baishideng Publishing Group Co.
World J Cardiol. Nov 26, 2013; 5(11): 410-419
Published online Nov 26, 2013. doi: 10.4330/wjc.v5.i11.410
Table 1 Summary of the major pacing and implantable cardioverter-defibrillator randomized trials that compared atrial (AAI or DDD) vs ventricular based pacing strategies
Ref.PatientsFollow-upPacing/ICDStudy groupsEndpointsResults
(n)(yr)indication
Danish study[8] (1997)2255.5SSSAAI vs VVIAll-cause mortality, CV mortality, AF, stroke, HF, and AV blockSignificant reduction in CV mortality, AF, stroke and HF in the AAI group
PASE[11] (1998)4071.5SSS and AVBDDDR vs VVIRQuality of life, all-cause mortality1, HF1, and AF1No overall difference in quality of life albeit moderate improvement in patients with SSS but not AVB in the DDDR group No difference in mortality, HF or AF
CTOPP[9] (2000)25686.4SSS and AVBDDD/AAI vs VVI(R)Stroke, CV mortality, all-cause mortality1, AF1, and HF1No difference in stroke, CV mortality, all-cause mortality or HF Significant reduction in AF in the DDD/AAI group.
MOST[10] (2002)20102.8SSSDDDR vs VVIRAll-cause mortality, stroke, AF1, HF1, QoL1, pacemaker syndrome1No difference in all-cause mortality, stroke Significant reduction in AF, HF, and QoL in the DDDR group 18.3% cross-over due to pacemaker syndrome in the VVIR group
UK-PACE[14] (2005)20213AVBDDD(R) vs VVI(R)All-cause mortality, AF1, HF1, stroke1No difference in any of the endpoints
DANPACE[13] (2011)14155.4SSSAAIR vs DDDRAll-cause mortality, AF1, HF1, stroke1, need for pacemaker reoperation1No difference in all-cause mortality, chronic AF, HF or stroke Increased risk of paroxysmal AF and need for pacemaker reoperation (development of AVB) in the AAIR group
DAVID[7] (2002)5060.8Primary and secondary prevention ICDVVI 40 vs DDDR 70 ICDComposite of hospitalization for HF and mortalityPrematurely interrupted due to increased occurrences of the composite endpoint in the DDDR 70 group
MADIT II substudy[17] (2005)12321.7Primary prevention ICD0%-50% vs 51%-100% VPComposite of HF and mortalityNearly two-fold increase in hospitalization for HF in the 51%-100% VP group